Abstract B123: FMC-220, a highly potent and selective covalent activator of p53 Y220C, is broadly active in p53 Y220C containing PDX models across cancer indications
Year: 2025
Type: conference-abstract
Source: Molecular Cancer Therapeutics
Authors: Kevin R. Webster, Yan Wang, Shayna Simonstein, Truc Nguyen, John-Paul Upton, Vikram Narayan, Karsten Krug, Tiep Le, Sarah Gilfillan, Shefali Sabhlok, Irina Dotsenko, Alessandra Ianari, Lata Jayaraman
Institution: Frontier Medicines (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4415444463
Cites:
Cited by:
Related to: